Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis-Reference-Cited by-同舟云学术

Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis

Published:2022-08 Issue: Volume:55 Page:152011
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Zhang Lining,Yang Hanbo,Yang Hongxia,Liu Hongyan,Tian Xiaolan,Jiang Wei,Peng Qinglin,Wang Guochun,Lu Xin

Funder

Beijing Municipal Science and Technology Commission

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference38 articles.

1. European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups;Lundberg;Arthritis Rheumatol,2017

2. Polymyositis and dermatomyositis (first of two parts);Bohan;N Engl J Med,1975

3. Polymyositis and dermatomyositis (second of two parts);Bohan;N Engl J Med,1975

4. The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome;Lu;Curr Opin Rheumatol,2019

5. Anti-TIF1-γ antibody and cancer-associated myositis–A clinicohistopathologic study;Hida;American Academy of Neurology,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatomiositis anti-TIF1γ positivo con compromiso pulmonar intersticial: reporte de dos casos;Revista Colombiana de Reumatología;2024-08

2. Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical–serological–pathological classification;Rheumatology;2024-07-19

3. Murine models of idiopathic inflammatory myopathies;The Journal of Dermatology;2024-02-06

4. Malignancies in systemic rheumatic diseases: A mini review;Frontiers in Immunology;2023-02-28

5. Biomarkers of disease activity in dermatomyositis;Current Opinion in Rheumatology;2022-08-30